Pharmaceutical Raw Materials

Valinolamine is an amino cyclic alcohol, which is the core structure of glycolytic enzyme inhibitors of Pseudoamino sugars. Many pseudoglucosaminidase inhibitors, such as acarbose and voglibose, contain validamycin and valinolamine in their structures. At the same time, valinolamine is also the component structure of biological pesticide validamycin. Valinolamine can be isolated from the fermentation broth of Streptomyces hygroscopicus. Valinolamine has a potent inhibitory effect on sucrase, maltase and isomaltase in pig intestines α- Glucosidase inhibitory activity.

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

Sevelamer carbonate is a commonly used phosphate binder, which delays the absorption of phosphate from the intestine, combines with the phosphoric acid in gastrointestinal food to form insoluble calcium phosphate and is discharged from the body. Sevelamer carbonate is a non calcium phosphate binder commonly used by renal dialysis patients in maintenance hemodialysis. It is recommended for clinical use because it does not increase blood calcium level, relatively few adverse reactions, and has high safety in long-term use. It can also be used to treat diabetes and nephropathy.

Afatinib is an innovative anti-cancer target drug, that is, a new generation of oral target drug. It is the first anti-cancer target drug in the world that irreversibly combines with ErbB family (including four different epidermal growth factor receptors of cancer cells, such as EGFR, HER2, ERBB3 and ErbB4), so as to more effectively and specifically block the signal that triggers the growth of cancer cells, Reduce or delay the proliferation of cancer cells. Alfatinib has been approved as a first-line treatment drug in the United States, Europe and Taiwan for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutant cancer cells. It is a daily oral target drug. Alfatinib was developed by German pharmaceutical company bringer Ingelheim. After a number of large-scale clinical trials, it was rated as a breakthrough treatment by FDA. The world authoritative academic journal nature also pointed out that "afatinib" has become one of the global positive headlines in 2013. Afatinib was listed in the United States and Europe in 2013, with the trade names of "gilotrif" and "giotrif" respectively; The Chinese trade names in Taiwan and Xiangkuang are "tuofuke" and "giotrif", respectively. The official use of the Chinese trade names is under review. By suppressing the signal transduction of ErbB family, it plays a key role in preventing tumor growth and proliferation. Alfatinib can irreversibly bind to ErbB family receptors, interrupt downstream information transmission, thus prevent cancer cell growth and induce apoptosis (programmed death). Therefore, compared with other target drugs, the irreversible binding of alfatinib to ErbB family receptors can provide more durable, selective, covalent and complete interruption of information transmission through cancer cells, thus bringing unique anti-cancer therapeutic benefits, more potential to inhibit the growth of a wide range of tumor cells, and more remarkable curative effect.

Pyridoxal phosphate is formed by the combination of vitamin B6 and phosphoric acid, including pyridoxal, pyridoxamine and pyridoxine. It exists in the form of phosphate ester in the body. Pyridoxal phosphate and pyridoxamine phosphate can be transformed into each other, and both of them are active. Pyridoxal phosphate is a coenzyme of aminotransferase and decarboxylase in amino acid metabolism, which can promote the decarboxylation of glutamic acid and promote the metabolism of glutamic acid γ- The formation of aminobutyric acid, which is a neurotransmitter. Pyridoxal phosphate, a coenzyme of citrulline and ornithine, is a drug used in the treatment of Parkinson's disease.